Novavax (NVAX) Stock Statistics & Valuation Metrics

Novavax has a market cap or net worth of $1.74B. The enterprise value is $1.77B.

Novavax has 162,935,940 shares outstanding. The number of shares has decreased by -2.65% in one year.

Novavax’s return on equity (ROE) is -3.45 and return on invested capital (ROIC) is 78.00%.

The current PE Ratio of Novavax is 2.5. Novavax’s PEG ratio is -0.00770.

In the last 12 months, Novavax had revenue of 1.12B and earned 440.30M in profits. Earnings per share was 2.72.

In the last 12 months, operating cash flow was -244.63M and capital expenditures -5.93M, giving a free cash flow of -250.57M billion.

Novavax pays an annual dividend of ―, resulting in a dividend yield of ―

Novavax upcoming earnings date is May 13, 2026, After Close (Confirmed).

Novavax as a current ratio of 2.13, with Debt / Equity ratio of -194.76%

In the past 12 months, Novavax has paid 1.86M in taxes.

Novavax EV to EBITDA ratio is 2.23, with an EV/FCF ratio of -4.38.

Novavax has $735.08M in cash and marketable securities with $248.81M in debt, giving a net cash position of $486.27M billion.

Gross margin is 93.32%, with operating margin of 50.14%, and net profit margin of 39.19%.

The average price target for Novavax is $12.67, which is 11.43% higher than the current price. The consensus rating is Hold